Medtronic (NYSE:MDT) Updates FY 2025 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 5.400-5.500 for the period, compared to the consensus estimate of 5.450. The company issued revenue guidance of $33.1 billion-$33.6 billion, compared to the consensus revenue estimate of $33.6 billion.

Medtronic Stock Performance

Shares of Medtronic stock opened at $82.29 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.03 and a quick ratio of 1.55. The firm has a 50 day simple moving average of $82.81 and a 200 day simple moving average of $82.83. Medtronic has a fifty-two week low of $68.84 and a fifty-two week high of $91.00. The firm has a market cap of $109.27 billion, a P/E ratio of 29.92, a P/E/G ratio of 2.69 and a beta of 0.78.

Medtronic (NYSE:MDT) last released its earnings results on Thursday, May 23rd. The medical technology company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.45 by $0.01. The company had revenue of $8.59 billion during the quarter, compared to analysts’ expectations of $8.44 billion. Medtronic had a return on equity of 13.47% and a net margin of 11.36%. The business’s revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the firm earned $1.57 EPS. Sell-side analysts predict that Medtronic will post 5.45 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 12th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.70 per share. This is a boost from Medtronic’s previous quarterly dividend of $0.69. This represents a $2.80 annualized dividend and a yield of 3.40%. The ex-dividend date is Friday, June 28th. Medtronic’s payout ratio is currently 101.82%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MDT. Mizuho raised their target price on shares of Medtronic from $95.00 to $98.00 and gave the company a buy rating in a research note on Wednesday, February 21st. Truist Financial reduced their price objective on shares of Medtronic from $90.00 to $88.00 and set a hold rating on the stock in a research note on Friday. Oppenheimer upped their target price on shares of Medtronic from $89.00 to $92.00 and gave the company a market perform rating in a research report on Wednesday, February 21st. Wells Fargo & Company raised their price target on Medtronic from $102.00 to $105.00 and gave the stock an overweight rating in a research report on Friday. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Medtronic in a research note on Friday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of Hold and an average price target of $94.00.

Insider Transactions at Medtronic

In related news, EVP Michael Marinaro sold 854 shares of Medtronic stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $83.14, for a total value of $71,001.56. Following the sale, the executive vice president now owns 27,925 shares of the company’s stock, valued at approximately $2,321,684.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.30% of the stock is owned by insiders.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.